This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
I became passionate about medical cannabis when I saw remarkable results using cannabis in treating my son Zach’s severe refractory epilepsy. After weeks of being turned down again and again from major businesses, I felt alone and discouraged.
GW Pharmaceuticals created the medication after studies showed surprising success treating severe childhood epilepsy, specifically Lennox-Gastaut Syndrome and Dravet Syndrome. Now, Marijuana Business Daily reports that the European Commission has just approved the drug as well. In the U.S., Epidiolex costs $32,000 USD per year.
If passed and put into practice, this bill would bring about major changes for cannabis users in Texas, as well as for businesses selling cannabis. The Texas medical cannabis program allows for no more than 0.5%
A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals. CBD-based treatment for people with Refractory Epilepsy?—?is Refractory Epilepsy is epilepsy that involves frequent and severe seizures that are difficult to treat. CannEpil™?—?CBD-based
–(BUSINESS WIRE)–Beginning in January 2024, natural medicine research nonprofits Realm of Caring, Unlimited Sciences and Lily’s Lighthouse will collaborate to collect data for an observational study on the efficacy of functional mushrooms in treating epilepsy. COLORADO SPRINGS, Colo.–(BUSINESS
Australia’s drugs regulator issues 73 infringement notices over claims prescriptions could treat conditions such as cancer and epilepsy. It is also alleged that the unlawful advertising included unapproved references to the treatment of serious diseases or conditions, including in some cases cancer and epilepsy.
DUBLIN–(BUSINESS WIRE)–The “Epilepsy – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. This Epilepsy – Pipeline Insight, 2021 provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Epilepsy pipeline landscape.
There are currently five “pharmaceutical processor” permit holders in Virginia, and they’re about to open for business. These were moms and dads and grandparents of children [with intractable epilepsy] who were using medical cannabis oils. As in, no to anyone who wasn’t an epilepsy patient.].
and its Scientific Advisory Board, the Organization Publishes New Real-World Study on Epilepsy and CBD. –(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., Under the Leadership of Nicolas Schlienz, Ph.D., COLORADO SPRINGS, Colo.–(BUSINESS
Under the prior regulations, only patients suffering from a certain list of conditions, like cancer, epilepsy, or HIV, could qualify for the medical marijuana program. House Bill 418 aims to provide extra protection for those businesses that operate within the parameters of Louisiana state law. House Bill 418. House Bill 211.
As of right now, the only cannabis-based medication officially recognized by the FDA is the CBD oral solution Epidiolex, which is used to treat two rare forms of childhood-onset epilepsy.
.” It is still an oddity in Australia but in many US states, medicinal cannabis medications including tetrahydrocannabinol (THC) — the psychoactive component in cannabis — are being used as a treatment for pets with conditions such as arthritis and epilepsy. It is a big and growing business. Read the full article at [link].
She came to the industry not from the recreational side, but as a mother seeking treatment for her child with epilepsy. In 2014, I was reading the Senate Bill 339 [Texas’ Compassionate Use Act enacted in 2015] testimony of mothers of children with epilepsy. Based on what I read on epilepsy I knew it had some success there.
European Cannabis Business News and Updates for This Week. With 19 licensed importers in Germany in the meanwhile, this represents an necessary time within the development of the nation’s medical cannabis business. Epidiolex is an epilepsy-fighting cannabis base drug produced by GW Prescription drugs.
Fortunately, at MGC Pharma, we are in the business of Medical Cannabis and have spent years researching and understanding the effects and phenotypes of different strains to determine which ones work best for different conditions, with each containing different amounts of THC, CBD and other components. You can learn more about it here.
–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Phase 2, Placebo-Controlled Clinical Study of Oral Ganaxolone in PCDH19-Clustering Epilepsy (the Violet Study). Marinus investor event: Marinus Pharmaceutical Virtual Investor Event at American Epilepsy Society 2021 Annual Meeting.
Are you considering getting into the growing and/or selling business and want to know how to promote your products to your customers? Medical marijuana is also known to be beneficial to those who deal with epilepsy and other seizure disorders. Throughout the U.S., Have you been wondering whether marijuana could be beneficial to you?
A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals Right now in Australia, access to Cannabis-based treatments is heavily restricted. kg of THC per annum for Epilepsy, MS and HIV/Aids sufferers alone. What will unrestricted access to Medicinal Cannabis look like in Australia?
As Hong Kong takes its first steps toward cracking down on cannabidiol, businesses specializing in CBD-infused beers, coffees and other products are scrambling to work out what comes next. which owns Found and supplies CBD products to other businesses in the city. For CBD-focused businesses, that may spell the beginning of the end.
–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. Nanomerics”) to use Nanomeric’s molecular envelope platform technology (MET) for the nasal delivery of a cannabidiol (CBD) for the management of epilepsy in adults and children.
The Food and Drug Administration (“FDA”) had a busy Monday this week. On November 25, the agency issued warning letters to 15 businesses selling hemp-derived CBD (“Hemp-CBD”) products as unapproved drugs. Epidiolex is used to treat epilepsy and requires a prescription. Warning Letters.
There are two main sections to the reform, one for businesses and the second for patients: Reform to cannabis business licensing process: The licensing process for cannabis research institutes and cannabis dispensing pharmacies expanded and clarified. This permit encompasses business planning and development pending final approval.
House Bill 136 was overwhelmingly approved in a vote of 16 to one after committee members heard from constituents who suffer from health problems such as epilepsy and chronic pain. Farmers could apply for a license to cultivate the crop, and processors, retailers, and labs testing facilities could also apply for separate business licenses.
Harper Howard’s family never saw her smile until age 3, when they administered hemp oil to treat the life-threatening genetic disorder CDKL5 epilepsy. Lily Howard, making history as one of the youngest guests to ever appear on Cannabis Talk 101, said “My sister Harper was born when I was 2.
Business Cann first reported on the development of the ‘Patient Registry for Cannabis-Based Products’, last year and the NHS has confirmed it will launch on April 1. ( The post NHS To Launch Its First Evidence-Based Cannabis Patient Data Registry This Week – Cannabis Business Executive appeared first on SpeedWeed.
Businesses want to broaden their advertising strategy now that it has touched the neighborhoods. Full spectrum distillate is being used to treat anything from muscular pains and anxiety to arthritis, epilepsy, and PTSD. They can also get high by eating a cookie or having a drink if they don’t feel like smoking. Final Thoughts.
Additionally, research, testing, and manufacturing licenses are reserved for businesses that are at least 30% Bahamian-owned. They will now be allowed to prescribe medical cannabis to treat conditions like depression, epilepsy, multiple sclerosis, post-traumatic stress disorder , and cancer.
drug regulators approved the first marijuana-based pharmaceutical to treat kids with a form of epilepsy, and billions of investment dollars poured into cannabis companies. company that develops software for marijuana retailers and businesses. Financial institutions are skittish about cannabis businesses, even in U.S.
The state still needs to staff the Office of Cannabis Management and the Cannabis Control Board, finalize the regulations for cannabis sellers, producters, and growers, and approve licenses for cannabis businesses. Not every city or town will necessarily have dispensaries or consumption lounges. The good news?
BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Supera-CBD is being developed to address anxiety, chronic pain, addiction, and seizures, and is on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain.
Some of the conditions include: cancer, terminal illness, depression, epilepsy, anxiety or panic disorder, chronic pain, spasticity, autism, Tourette syndrome and post-traumatic stress disorder. . Businesses that are awarded those licenses could operate up to three sites in different counties, according to the Senate bill’s text.
. “Most importantly, there is no definitive evidence as yet that CBD would work for any of the myriad health conditions which it is supposed to benefit, except for certain types of epilepsy.” LDN CBD launched in 2018 to tap into the new market, and is seeking a new round of financing to fund expansion. ” [link]. .
Hundreds of thousands of patients around the world rely on cannabis medicine to treat a range of conditions, including epilepsy, Parkinsons, cancer, PTSD, Crohn’s disease, autism, chronic pain and more. I am pleased to read that cannabis dispensaries are being classified as essential businesses in the U.S.
The state recently awarded cultivation licenses to six growers, all of whom are expected to launch their businesses in the next few months. The commission maintains that the scoresheets for each competing company – most of which kept their business information concealed from the public – are confidential.
As per the proposed bill, multiple sclerosis (MS), Parkinson’s disease , epilepsy , post-traumatic stress disorder (PTSD), and HIV/AIDS are some examples of medical conditions featured on the list of qualifying criteria. North Carolina Ought to Catch Up with the Rest of the U.S.
Legislation is pending, Senate Bill 51, to assist financial institutions in safely conducting transactions with licensed cannabis businesses. Click here to email your lawmakers in support of expanded medical access. Update : SB 51 was approved by the Senate on 5/21/19, and now heads to the Assembly. CA resident?
The passage of the 2018 Farm Bill and the legalization of hemp and hemp-derived products has sparked strong business interest from foreign stakeholders. This blog posts briefly addresses the risks and feasibility of engaging in this business at the moment. IMPORTING HEMP.
Due to the growing popularity and mainstream nature of CBD-infused products, many alcohol beverage companies were surprised to read us conclude that blending CBD into their products was a risky business, even in hemp-friendly states like Oregon. As we have discussed at length since the enactment of the 2018 Farm Bill (e.g.,
BOSTON–(BUSINESS WIRE)– #ANXIETY–Quolet, a private clinical stage biopharmaceutical company, is announcing the completion of a Phase 1 healthy volunteer study evaluating pure Cannabidiol (CBD) (clinicaltrials.gov NCT05032807).
New businesses have emerged, and existing companies have expanded to support the industry’s various needs. MMJ is known for its efficacy in treating various medical issues, including chronic pain, epilepsy, multiple sclerosis, and more. The positive effects extend to patients, families, caregivers, and local businesses.
If until recently working with cannabis was taboo for law firms, having experience in this niche today has become a lure of clients and new business opportunities as interesting as opening up an incipient sector with the potential to move millions of reais in the Brazil in the coming years.
The HSS also pointed out studies with weaker evidence suggesting cannabis can potentially help with conditions like PTSD , epilepsy , and anxiety. That said, rescheduling will definitely remedy one major headache for cannabis business owners — taxes! This means massive tax savings for cannabis businesses!
The FDA has approved of Epidiolex, which contains CBD, for treating epilepsy. We’ll wrap up our conversation by providing some tips on how to advise businesses in this complicated space. Top Five Things Your CBD Business Needs to Consider. The FDA’s Stance on Hemp-Derived CBD as a Dietary Supplement (Part 2).
DUBLIN–(BUSINESS WIRE)–The “Medical Cannabis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026” report has been added to ResearchAndMarkets.com’s offering. The global medical cannabis market exhibited strong growth during 2015-2020. during 2021-2026. 2 Scope and Methodology.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content